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Bleeding Avoidance StrategiesI greatly appreciate the interest of Dr. Woronow in
my recent study published in the Journal (1). Prot-
amine binds with heparin or low-molecular-weight
heparin to form a stable ion pair with no anticoagu-
lant activity. This compound is routinely used during
cardiopulmonary bypass surgery and is also admin-
istered to reverse the effect of heparin in patients in
stable condition after invasive cardiac catheterization
(e.g., post-transplant evaluation, fractional ﬂow
reserve estimation not requiring percutaneous coro-
nary interventions [PCIs]). Protamine, as mentioned
by the author, is not only important to reverse anti-
coagulation in case of major bleeding after PCI, but it
is also crucial in the uncommon event of cardiac or
coronary perforation during procedures that require
large doses of heparin (2).
There are several reasons that protamine cannot be
routinely used to avoid bleeding after PCI. First, the
allergic reactions to protamine are not uncommon
and can lead to serious anaphylaxis. Second, even
though protamine has been shown to be safe in small
series, case-control, and randomized studies, its
usefulness has not been proven in large contempo-
rary randomized trials (3). Third, its safety has been
tempered with case reports of ischemic complications
in patients treated with protamine (4). Fourth, the
use of the radial artery for access has diminished theutility of protamine reversal in favor of radial artery
patency requiring anticoagulation with heparin.
The role of protamine should be explored further,
and larger, randomized trials need to be planned. In
the meantime, patient selection for use of protamine
is important. Patients with seafood allergies or pre-
vious use of protamine should not be given this drug.
However, patients at very high risk of bleeding (e.g.,
elderly women presenting with acute coronary syn-
drome and who had femoral access for PCI) would be
ideal candidates for protamine administration for
heparin reversal, especially if there are bleeding
events (i.e., hematoma, retroperitoneal bleed).
Rebound thrombogenicity and allergic reactions
to protamine are valid concerns that need to be
addressed. Protamine remains a useful tool in the
armamentarium of interventional cardiologists, and
its judicious use is recommended.*Mandeep Singh, MD, MPH
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Trial Data Into a Hybrid
AmericanCollegeof Cardiology/
American Heart Association
Algorithm for the Allocation
of Statin Therapy in
Primary Prevention
Ridker et al. (1) draw attention to the importance of
statins as primary prevention agents; they endorse
